New drug duo aims to outperform chemo in rare ovarian cancer
NCT ID NCT07002346
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether a new immunotherapy drug (QL1706) combined with bevacizumab can slow cancer growth better than standard chemotherapy in women with advanced ovarian clear cell carcinoma. About 226 participants will be randomly assigned to receive either the experimental combo or chemo (with or without bevacizumab). The study tracks how long the cancer stays under control and monitors side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a drug that targets two immune checkpoints, PD-1 and CTLA-4) plus bevacizumab
- What this could lead to
- If it works, this could offer a new first-line treatment option that delays cancer progression better than standard chemotherapy for women with advanced ovarian clear cell carcinoma.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. The experimental combination may not improve outcomes and could cause side effects like immune-related inflammation or bleeding risks from bevacizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CLEAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug missile take down a tough ovarian cancer?
- New pill aims to shrink Hard-to-Treat cancers
- New targeted drug shows promise for Hard-to-Treat gynecologic cancers
- New drug aims to reactivate Cancer-Fighting genes in solid tumors
- New drug combo shows promise for tough ovarian cancer
- New triple therapy takes on hard-to-treat ovarian cancer